Home > PJ (current issue) > Leading article | Search

Return to PJ Online Home Page

The Pharmaceutical Journal
Vol 271 No 7266 p310
13 September 2003

This article
Reprint
Photocopy

Leading Article

Benefit of hindsight

With the benefit of hindsight, some members of the Council of the Royal Pharmaceutical Society might now wish that the consultation exercise for the proposed new Charter had been halted immediately after the Special General Meeting held at the beginning of June. At the Council meeting held in the same week as the SGM, it was agreed that the “seeking of charitable status” for the Society would be put on the back burner. In which case, it might have been argued, the draft Charter was no longer applicable, as it seems partly to have been designed to pave the way for charitable status. Instead, an amended draft might have been created that makes the changes necessary to strengthen the Society’s regulatory role, but does not undermine the professional representative role.

If that had happened, many of the members who responded to the consultation exercise might have been reassured. As it is, the independent feedback report published in this week’s issue (p349) suggests that they are far from happy. Of course, the adage that you can never please all the people all of the time is true in bucketsful when it comes to the Society’s and Council’s dealings with the membership.

Moreover, the percentage of members who care whether the Society is a charity, a chartered body or whatever (other than a means of ensuring they can practise as pharmacists) is likely to be well below 50. It is no coincidence that the number of responses analysed in the feedback report (just over 400) — even allowing for the fact that quite a few represented the collective response from branch and other meetings — fell far short of the nearly 8,000 responses to the consultation on continuing professional development. Part of that can be explained by the complexities of modernisation. You have to be a pretty dedicated Society-watcher to understand all the legal niceties of the Charter and the modernisation process: the Powers, Objects, Section 60, etc.

Nevertheless, the Council is faced with something of a challenge — convincing the membership that it will take their anxieties about the draft Charter on board.

Transparency is the key to this. Those in the hot seat should be congratulated for having the guts to publish the feedback — warts and all — without commentary or apology because it does not make comfortable reading. Given that decision, The Journal has high hopes that the President and the Council, after they have discussed the report and its implications for the Charter, will be able to have most of the concerned members back on side by the end of the year.

Back to Top


Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal